Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Alexanian

Showing results (131-140 of 196) with videos related to

Pageof 20
Sort By:
Blood|January 15, 1994
Limited value of myeloablative therapy for late multiple myelomaR Alexanian, M Dimopoulos, T Smith, et al.
Stem Cells and Development|May 20, 2008
In vitro and in vivo characterization of neurally modified mesenchymal stem cells induced by epigenetic modifiers and neural stem cell environmentArshak R Alexanian, Dennis J Maiman, Shekar N Kurpad, et al.
American Journal of Hematology|June 1, 1996
HyperCVAD for VAD-resistant multiple myelomaM A Dimopoulos, D Weber, H Kantarjian, et al.
Blood|February 1, 1988
Plasma cell karyotype in multiple myelomaJ Gould, R Alexanian, A Goodacre, et al.
Blood|May 15, 1990
Fludarabine therapy in macroglobulinemic lymphomaH M Kantarjian, R Alexanian, C A Koller, et al.
Cancer|January 1, 1983
Anaplastic myeloma with massive extramedullary involvement. Report of two casesK Foucar, M Raber, E Foucar, et al.
Blood|March 1, 1980
Cellular DNA content as a marker of human multiple myelomaJ Latreille, B Barlogie, G Dosik, et al.
Cancer|March 1, 1977
Tumor growth patterns in multiple myelomaJ A Hokanson, B W Brown, J R Thompson, et al.
Cancer Treatment Reports|March 1, 1984
Addition of cisplatin and bleomycin to vincristine-carmustine-doxorubicin-prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group studyJ D Bonnet, R Alexanian, S E Salmon, et al.
The Journal of Clinical Investigation|September 1, 1983
Marrow cytometry and prognosis in myelomaB Barlogie, R Alexanian, E A Gehan, et al.
Pageof 20

Showing results (131-140 of 196) with videos related to

Sort By:
Pageof 20
Blood|January 15, 1994
Limited value of myeloablative therapy for late multiple myelomaR Alexanian, M Dimopoulos, T Smith, et al.
Stem Cells and Development|May 20, 2008
In vitro and in vivo characterization of neurally modified mesenchymal stem cells induced by epigenetic modifiers and neural stem cell environmentArshak R Alexanian, Dennis J Maiman, Shekar N Kurpad, et al.
American Journal of Hematology|June 1, 1996
HyperCVAD for VAD-resistant multiple myelomaM A Dimopoulos, D Weber, H Kantarjian, et al.
Blood|February 1, 1988
Plasma cell karyotype in multiple myelomaJ Gould, R Alexanian, A Goodacre, et al.
Blood|May 15, 1990
Fludarabine therapy in macroglobulinemic lymphomaH M Kantarjian, R Alexanian, C A Koller, et al.
Cancer|January 1, 1983
Anaplastic myeloma with massive extramedullary involvement. Report of two casesK Foucar, M Raber, E Foucar, et al.
Blood|March 1, 1980
Cellular DNA content as a marker of human multiple myelomaJ Latreille, B Barlogie, G Dosik, et al.
Cancer|March 1, 1977
Tumor growth patterns in multiple myelomaJ A Hokanson, B W Brown, J R Thompson, et al.
Cancer Treatment Reports|March 1, 1984
Addition of cisplatin and bleomycin to vincristine-carmustine-doxorubicin-prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group studyJ D Bonnet, R Alexanian, S E Salmon, et al.
The Journal of Clinical Investigation|September 1, 1983
Marrow cytometry and prognosis in myelomaB Barlogie, R Alexanian, E A Gehan, et al.
Pageof 20